A five coordination Cu(<scp>ii</scp>) cluster-based MOF and its application in the synthesis of pharmaceuticals via sp<sup>3</sup> C–H/N–H oxidative coupling
作者:Thuan V. Tran、Hanh T. N. Le、Hiep Q. Ha、Xuan N. T. Duong、Linh H.-T. Nguyen、Tan L. H. Doan、Ha L. Nguyen、Thanh Truong
DOI:10.1039/c7cy00882a
日期:——
fully characterized. This material was demonstrated to be an efficient heterogeneous catalyst for the oxidative C–H activation via N–H bonds. The optimized conditions are applicable for the synthesis of pharmaceuticals constructed by α-amino carbonyl skeletons.
the first time to synthesize pharmaceutically important α-aminoketonesfrom readily available benzylic secondary alcohols and amines using N-bromosuccinimide. This new reaction proceeds via three consecutive steps involving oxidation of alcohols, α-bromination of ketones, and nucleophilic substitution of α-bromo ketones to give α-aminoketones. Importantly, this novel one-pot greener reaction avoids
The current invention provides an improved immunoassay for the detection and determination of pyrrolidinophenone based designer drugs in hair and biological fluids (urine, blood, and oral fluid). The generic immunoassay is underpinned by novel, sub-family-specific antibodies, which display surprising sensitivity. The invention further describes substrates comprising an antibody that is specific to compounds of the pyrrolidinophenone family. Also described are the novel immunogens from which the antibodies are derived and kits incorporating the antibodies of the current invention.
Pyrovalerone Analogues and Therapeutic Uses Thereof
申请人:Butler David
公开号:US20080234498A1
公开(公告)日:2008-09-25
New compounds that bind to monoamine transporters are described. The compounds of the present invention can be racemic or pure R— or S-enantiomers. Certain preferred compounds of the present invention have a high selectively dopamine transporter versus the serotonin transporter. Preferred monoamine transporters for the practice of the present invention include the dopamine transporter, the serotonin transporter and the norepinephrine transporter.
The current invention provides an improved immunoassay for the detection and determination of pyrrolidinophenone based designer drugs in biological fluids (Urine, Blood, Oral fluid and Hair). The generic immunoassay is underpinned by novel, subfamily-specific antibodies which display surprising sensitivity. The invention further describes substrates comprising an antibody that is specific to compounds of the pyrrolidinophenone family. Also described are the novel immunogens from which the antibodies are derived and kits incorporating the antibodies of the current invention.